Overview
ZBIO market data
Price History
ZBIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.44 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.70 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.50 – $44.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.9K · P/B 8.05.
Company News
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga · Jun 12, 2026, 12:05 PM
Zenas BioPharma Submits An FDA Biologics License Application For Obexelimab In Immunoglobulin G4-Related DiseaseBenzinga · May 28, 2026, 11:20 AM
Zenas BioPharma Announces That Safety And Efficacy Outcomes From The Phase 3 INDIGO Trial Will Be Presented At The European Alliance Of Associations For Rheumatology Congress, June 3-6Benzinga · May 19, 2026, 11:15 AM
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $22Benzinga · May 14, 2026, 5:27 PM
Earnings Scheduled For May 13, 2026Benzinga · May 13, 2026, 11:11 AM
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobenewswire Inc · May 13, 2026, 11:00 AM
Zenas BioPharma Does First Patient In Its Phase 1 Trial Of ZB021, A Novel Oral IL-17AA/AF InhibitorBenzinga · May 13, 2026, 10:52 AM
Zenas BioPharma Q1 EPS $(1.46) Misses $(1.17) EstimateBenzinga · May 13, 2026, 10:32 AM
8-K filing — Zenas BioPharma, Inc. (ZBIO)SEC EDGAR · May 13, 2026, 10:14 AM